Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Genomic profiling may reveal new drug targets in urothelial carcinoma

Share :

2015 Genitourinary Cancers Symposium
Published: 27 Feb 2015
Views: 4574
Rating:
Save
Dr Jeffrey Ross - Albany Medical College, Albany, USA

Urinary bladder urothelial carcinoma is a devastating disease with extremely limited treatment options - how can we find new drug targets for it?

Dr Jeffrey Ross talks to ecancertv at ASCO GU 2015 about his work on the genomic profiling of bladder carcinoma, looking for genetic alterations that will give clues for future treatments. 

Related Videos

ASCO GU 2026: Updates in metastatic prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina
ASCO GU 2026: Updates in metastatic prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )
17 Mar 2026

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )
28 Oct 2024

Understanding the use of PARPi combinations to treat patients with mCRPC

Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard
Understanding the use of PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard )
15 Sep 2024

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg
ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )
15 Sep 2024

Addressing the rise of multiple myeloma in Rwanda

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda
Addressing the rise of multiple myeloma in Rwanda ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )
6 Aug 2024

Durable responses in aRCC, how do we optimise treatment?

Prof Roberto Iacovelli and Prof Viktor Grünwald
Durable responses in aRCC, how do we optimise treatment? ( Prof Roberto Iacovelli and Prof Viktor Grünwald )
30 Jul 2024

Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis
Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis )
7 Jun 2024

Cabozantinib and atezolizumab show more efficacy compared to second NHT in patients with mCRPC

Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA
Cabozantinib and atezolizumab show more efficacy compared to second NHT in patients with mCRPC ( Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA )
30 Jan 2024

Molecular profiling in prostate cancer: key challenges for clinical implementation

Dr Joaquin Mateo - Vall d’Hebron Institute of Oncology, Barcelona, Spain
Molecular profiling in prostate cancer: key challenges for clinical implementation ( Dr Joaquin Mateo - Vall d’Hebron Institute of Oncology, Barcelona, Spain )
24 Oct 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation